By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Pharmaxis Ltd 

Unit 2, 10 Rodborough Road

Frenchs Forest  New South Wales  2086  Australia
Phone: 61-2-9451-5961 Fax: 61-2-9451-3622

Pharmaxis is a specialist pharmaceutical company committed to the research, development and commercialisation of human therapeutic products that improve the clinical management of chronic respiratory and autoimmune diseases.

Pharmaxis has a diversified portfolio of products at various stages of development which target attractive international markets across a range of diseases.

AridolTM: addresses a new market - providing a clinical management tool for asthma and COPD. It is scheduled to complete Phase III clinical trials in Q3 of 2004, with the initial product launch scheduled for Q3 of 2005.

BronchitolTM: a new therapeutic targeting cystic fibrosis, bronchiectasis, and chronic bronchitis. It is scheduled to complete Phase II clinical trials in H2 of 2004, with Phase III clinical trials scheduled to commence in H1 of 2005. The initial product launch is scheduled for CY 2008

PXS25: inhibits immune cell trafficking and is being developed for the treatment of multiple sclerosis and other autoimmune diseases.

PXS2000: represents a new class of anti-inflammatory agent under development for rheumatoid arthritis.

Pharmaxis is building a fully integrated specialist pharmaceutical company with activities spanning research and development through to manufacture, marketing, and distribution.

The company's board of directors and senior management team has extensive experience in developing and commercializing successful breakthrough products.

Last Updated: 05-20-04

Key Statistics

Ownership: Public

Web Site: Pharmaxis
Symbol: PXS.AX


Company News
Pharmaxis (PXS.AX) Boehringer Ingelheim Is Initiating Phase Iia Study For The Development Of A New Treatment For Diabetic Retinopathy - A Leading Cause Of Vision-Loss 9/8/2017 8:45:21 AM
Boehringer Ingelheim Initiates Phase IIa Study Of Compound Acquired From Pharmaxis (PXS.AX) In Debilitating Liver Disease NASH 8/25/2017 6:56:36 AM
Pharmaxis (PXS.AX) Releases Successful Results Of Phase 1 Clinical Trial For Boehringer Ingelheim Partnered Drug PXS-4728A 9/22/2015 9:08:47 AM
Pharmaxis (PXS.AX) And Synairgen plc Announce Research Collaboration To Develop LOXL2 Inhibitor For Pulmonary Fibrosis 8/5/2015 6:29:49 AM
Boehringer Ingelheim Acquires Pharmaxis (PXS.AX)’ Phase 1 Anti-Inflammatory Drug Candidate 5/18/2015 11:08:03 AM
Pharmaxis (PXS.AX) Shares Catapult on $750 Million Liver Drug Sale to Boehringer Ingelheim 5/18/2015 6:09:16 AM
Pharmaxis Ltd (PXS.AX) Slashes 30 Pct. of Jobs 5/28/2013 7:32:43 AM
Pharmaxis Ltd (PXS.AX) Chief Steps Down in Shake-Up 3/12/2013 7:47:25 AM
Pharmaxis Ltd (PXS.AX) Reels After Verdict on Key Drug, Bounces Back With $40 Million in Pocket 1/31/2013 8:08:20 AM
Pharmaxis Ltd (PXS.AX) Receives Approval to Market Bronchitol in the EU 4/27/2012 8:23:34 AM